Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361:1872–85.

Article  CAS  PubMed  Google Scholar 

Khoury J, Solary E, Abla O, Akkari Y, Alaggio R, Apperley J, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–19.

Article  PubMed  PubMed Central  Google Scholar 

Arber D, Orazi A, Hasserjian R, Borowitz M, Calvo K, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88.

Article  CAS  PubMed  Google Scholar 

Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503–10.

Article  PubMed  Google Scholar 

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Ossa JA, Nannya Y, et al. Molecular International Prognostic Scoring System for myelodysplastic syndromes. NEJM Evid. 2022; 1. https://doi.org/10.1056/EVIDoa2200008.

Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008;22:538–43.

Article  CAS  PubMed  Google Scholar 

Brunner AM, Leitch HA, van de Loosdrecht AA, Bonadies N. Management of patients with lower-risk myelodysplastic syndromes. Blood Cancer J. 2022;12:166.

Article  PubMed  PubMed Central  Google Scholar 

Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, et al. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT. Bone Marrow Transpl. 2017;52:209–15.

Article  CAS  Google Scholar 

Lim Z, Brand R, Martino R, Biezen A, Finke J, Bacigalupo A, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol. 2009;28:405–11.

Article  PubMed  Google Scholar 

Koreth J, Pidala J, Perez W, Deeg H, Garcia-Manero G, Malcovati L, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol. 2013;31:2662–70.

Article  PubMed  PubMed Central  Google Scholar 

DeFilipp Z, Ciurea SO, Cutler C, Robin M, Warlick E, Nakamura R, et al. Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines. Transpl Cell Ther. 2023;29:71–81.

Article  CAS  Google Scholar 

Ishiyama K, Aoki J, Itonaga H, Uchida N, Takahashi S, Ohno Y, et al. Graft-versus-MDS effect after unrelated cord blood transplantation: a retrospective analysis of 752 patients registered at the Japanese Data Center for Hematopoietic Cell Transplantation. Blood Cancer J. 2019;9:31.

Article  PubMed  PubMed Central  Google Scholar 

Itonaga H, Ishiyama K, Aoki K, Ishikawa T, Uchida N, Ohashi K, et al. Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60-69 years with myelodysplastic syndrome. Ann Hematol. 2019;98:1367–81.

Article  CAS  PubMed  Google Scholar 

Konuma T, Itonaga H, Ishiyama K, Hamamura A, Uchida N, Ozawa Y, et al. Progress in survival following three decades of allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: A real-world registry study in Japan. Am J Hematol. 2023;98:E68–E71.

Article  PubMed  Google Scholar 

Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Pérez WS, Anasetti C, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579–85.

Article  CAS  PubMed  Google Scholar 

Alessandrino EP, Della Porta MG, Malcovati L, Jackson CH, Pascutto C, Bacigalupo A, et al. Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Am J Hematol. 2013;88:581–8.

Article  PubMed  PubMed Central  Google Scholar 

de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129:1753–62.

Article  PubMed  PubMed Central  Google Scholar 

Saber W, Cutler CS, Nakamura R, Zhang MJ, Atallah E, Rizzo JD, et al. Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood. 2013;122:1974–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Itonaga H, Ishiyama K, Aoki K, Aoki J, Ishikawa T, Ohashi K, et al. Clinical impact of the loss of chromosome 7q on outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 2019;54:1471–81.

Article  CAS  Google Scholar 

de Witte T, Brand R, van Biezen A, Mufti G, Ruutu T, Finke J, et al. Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival. Br J Haematol. 2009;146:627–36.

Article  PubMed  Google Scholar 

Lee S, Kim Y, Yahng S, Cho B, Eom K, Lee S, et al. Survival benefits from reduced-intensity conditioning in allogeneic stem cell transplantation for young lower-risk MDS patients without significant comorbidities. Eur J Haematol. 2011;87:510–20.

Article  CAS  PubMed  Google Scholar 

Choi EJ, Lee J, Lee J, Kim D, Park H, Seol M, et al. Non-myeloablative conditioning for lower-risk myelodysplastic syndrome with bone marrow blasts less than 5%-a feasibility study. Ann Hematol. 2016;95:1151–61.

Article  PubMed  Google Scholar 

Atsuta Y. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol. 2016;103:3–10.

Article  PubMed  Google Scholar 

Kanda J. Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation. Int J Hematol. 2016;103:11–19.

Article  CAS  PubMed  Google Scholar 

Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol. 2007;86:269–74.

Article  PubMed  Google Scholar 

Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transpl. 2009;15:367–9.

Article  Google Scholar 

Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Bone Marrow Transpl. 2009;15:1628–33.

Article  Google Scholar 

Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125:1333–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Solh M, Zhang X, Connor K, Brown S, Solomon SR, Morris LE, et al. Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center. Biol Blood Marrow Transpl. 2016;22:1403–9.

Article  Google Scholar 

Xing R, Li C, Gale R, Zhang Y, Xu Z, Qin T, et al. Monosomal karyotype is an independent predictor of survival in patients with higher-risk myelodysplastic syndrome. Am J Hematol. 2014;89:E163–E8.

Article  PubMed  Google Scholar 

Della Porta MG, Alessandrino E, Bacigalupo A, Lint M, Malcovati L, Pascutto C, et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood. 2014;123:2333–42.

Article  PubMed  Google Scholar 

Mehta R, Holtan S, Wang T, Hemmer M, Spellman S, Arora M, et al. Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol. 2020;38:2062–76.

Article  PubMed  PubMed Central  Google Scholar 

Mehta R, Holtan SG, Wang T, Hemmer M, Spellman S, Arora M, et al. GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. Blood Adv. 2019;3:1441–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706.

Article  CAS  PubMed  Google Scholar 

Fine JP, Gray RJ. A proportional hazards model for subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.